ARTICLE | Clinical News
Aeterna begins third pivotal trial of Neovastat
December 19, 2000 8:00 AM UTC
Aeterna (AELA; TSE:AEL) began a pivotal Phase II trial of its Neovastat (AE941) oral inhibitor of angiogenesis as monotherapy in 120 patients with progressive multiple myeloma in North America and Eur...